Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
about
Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approachingPredictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start HemodialysisFactors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patientsNovel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Activation of the Nrf2-ARE Signaling Pathway Prevents Hyperphosphatemia-Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells.Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patientsNew therapeutic strategies under development to halt the progression of renal failure.Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.Next-generation phosphate binders: focus on iron-based binders.Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.Iron-based phosphate binders--a new element in management of hyperphosphatemia.Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.Effect of diet-derived advanced glycation end products on inflammation.Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.Sevelamer crystals in the mucosa of the gastrointestinal tract in a teenager with end-stage renal disease.Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin-1 production.A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on D
P2860
Q28071582-1EF7928C-E675-44B2-9BC0-6BDBA0D85CA2Q28078020-1FE3A030-CB3F-4C19-8FA5-695216424113Q28468444-E1675D76-2AC3-4E50-928B-47E6FA9CEB24Q35967669-861B60E9-C269-4D53-B472-368BBB683B46Q36225208-D5F80BF7-D924-46C1-86AE-A0BDE53AD67BQ36322947-F99727B6-8F15-4AE7-8693-1C351A5F39FFQ36373954-A1AE48DF-F4EB-498E-86B1-452F68089D69Q36951232-21360A22-67C4-4801-9EF1-C233DA383ECFQ38201504-B5988CF4-DD51-4D4D-912F-DC59AEE49D81Q38210438-FB0FDF1C-69EA-47EF-8A00-AE78738DC45EQ38213502-724A6732-2BD3-4876-836C-201A08335741Q38231646-C4CB8485-236D-4860-B54C-2E6E82CB0D47Q38253227-32A7E385-949E-41FA-9D94-D1401623DF8DQ38295285-FC54F1FF-8714-46D4-B87B-C7C97E3AAF18Q38389206-DD4A8908-BFE1-4998-BC64-A504B5DEC100Q38588208-730E050B-68BA-4AF2-BC25-6FC411F83C94Q42725751-3FE2EDAE-A2EA-453A-BAD5-93CA337B7D7EQ46265256-18D69A00-22BC-48CB-9C8C-03B5F17E486BQ46313956-F8604351-0C2D-4CBB-AAFB-2AA99D0688E5Q59109974-F7286232-10D4-4556-B314-1EF239D72087
P2860
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@en
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@nl
type
label
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@en
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@nl
prefLabel
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@en
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@nl
P2860
P921
P356
P1476
Sevelamer revisited: pleiotrop ...... e and end-stage renal disease.
@en
P2093
Anjay Rastogi
P2860
P304
P356
10.1177/1753944713513061
P5008
P577
2013-12-01T00:00:00Z